Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary

Michael Hutchinson

doi:10.1177/1352458514545144

Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary

Michael Hutchinson

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	1302-1303
Number of pages	2
Journal	Multiple Sclerosis Journal
Volume	20
Issue number	10
DOIs	https://doi.org/10.1177/1352458514545144
State	Published - Sep 2014
Externally published	Yes

Access to Document

10.1177/1352458514545144

Cite this

@article{8cbf72e525584ec8b9ff589971b87e7c,

title = "Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary",

author = "Michael Hutchinson",

note = "Funding Information: I side with Jenkins and Toosy; before we can promote OCT in the clinic as a tool to assess cerebral atrophy we need more evidence. In particular, we need more longitudinal studies demonstrating correlations with MRI measures over a number of years. We also need to determine uniform methods of assessment and reporting OCT; recent papers from a consensus group, validating such criteria, is a step in this direction. 11 , 12 The report from Peter Calabresi{\textquoteright}s lab that OCT measures need to be corrected for intracranial volume 4 (and also for eye length? 2 ) indicates that this technique is still in research development; it would be premature to suggest that MS clinical centres should take it up routinely as a surrogate measure of cerebral atrophy. Conflict of interest Michael Hutchinson served on a medical advisory board for the CONFIRM study [BG00012] for Biogen Idec, serves on the editorial board of the Multiple Sclerosis Journal , has received speaker{\textquoteright}s honoraria from Merck-Serono, Novartis, Biogen Idec and Bayer-Schering and receives research support from Dystonia Ireland, the Health Research Board of Ireland and the Foundation for Dystonia Research. ",

year = "2014",

month = sep,

doi = "10.1177/1352458514545144",

language = "English",

volume = "20",

pages = "1302--1303",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "10",

}

TY - JOUR

T1 - Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis

T2 - Commentary

AU - Hutchinson, Michael

N1 - Funding Information: I side with Jenkins and Toosy; before we can promote OCT in the clinic as a tool to assess cerebral atrophy we need more evidence. In particular, we need more longitudinal studies demonstrating correlations with MRI measures over a number of years. We also need to determine uniform methods of assessment and reporting OCT; recent papers from a consensus group, validating such criteria, is a step in this direction. 11 , 12 The report from Peter Calabresi’s lab that OCT measures need to be corrected for intracranial volume 4 (and also for eye length? 2 ) indicates that this technique is still in research development; it would be premature to suggest that MS clinical centres should take it up routinely as a surrogate measure of cerebral atrophy. Conflict of interest Michael Hutchinson served on a medical advisory board for the CONFIRM study [BG00012] for Biogen Idec, serves on the editorial board of the Multiple Sclerosis Journal , has received speaker’s honoraria from Merck-Serono, Novartis, Biogen Idec and Bayer-Schering and receives research support from Dystonia Ireland, the Health Research Board of Ireland and the Foundation for Dystonia Research.

PY - 2014/9

Y1 - 2014/9

UR - http://www.scopus.com/inward/record.url?scp=84925863776&partnerID=8YFLogxK

U2 - 10.1177/1352458514545144

DO - 10.1177/1352458514545144

M3 - Article

C2 - 25160124

AN - SCOPUS:84925863776

SN - 1352-4585

VL - 20

SP - 1302

EP - 1303

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

IS - 10

ER -